Research programme: Duchenne muscular dystrophy therapeutics - CombinatoRxAlternative Names: DMD therapeutics - CombinatoRx/Charley's Fund/Nash Avery Foundation
Latest Information Update: 22 Sep 2010
At a glance
- Originator CombinatoRx
- Developer Zalicus
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Muscular dystrophies
Most Recent Events
- 15 May 2009 Early research development is ongoing in USA
- 09 Nov 2007 Early research in Muscular dystrophy in USA (unspecified route)